• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA生物信息学分析确定HDAC通路为现有抗COVID-19疗法的潜在靶点。

MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics.

作者信息

Teodori Laura, Sestili Piero, Madiai Valeria, Coppari Sofia, Fraternale Daniele, Rocchi Marco Bruno Luigi, Ramakrishna Seeram, Albertini Maria Cristina

机构信息

Diagnostics and Metrology Laboratory, FSN-TECFIS-DIM, ENEA Frascati, Roma, Italy.

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.

出版信息

Front Pharmacol. 2020 Dec 8;11:582003. doi: 10.3389/fphar.2020.582003. eCollection 2020.

DOI:10.3389/fphar.2020.582003
PMID:33363465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7753186/
Abstract

Over 313,000 SARS-CoV-2 positive cases have been confirmed in Italy as of 30 September 2020, and the number of deaths exceeding thirty-five thousand makes Italy among the list of most significantly affected countries in the world. Such an enormous occurrence of infections and death raises the urgent demand for effective available treatments. Discovering the cellular/molecular mechanisms of SARS-CoV-2 pathogenicity is of paramount importance to understand how the infection becomes a disease and how to plan any therapeutic approach. In this regard, we performed an analysis to predict the putative virus targets and evidence the already available therapeutics. Literature experimental results identified angiotensin-converting enzyme ACE and Spike proteins particularly involved in COVID-19. Consequently, we investigated the signalling pathways modulated by the two proteins through query miRNet, the platform linking miRNAs, targets, and functions. Our bioinformatics analysis predicted microRNAs (miRs), miR-335-5p and miR-26b-5p, as being modulated by Spike and ACE together with histone deacetylate (HDAC) pathway. Notably, our results identified ACE/ACE2-ATR1-Cholesterol-HDAC axis signals that also matched with some available clinical data. We hypothesize that the current and EMA-approved, SARS-CoV-2 off-label HDAC inhibitors (HDACis) drugs may be repurposed to limit or block host-virus interactions. Moreover, a ranked list of compounds is provided for further evaluation for safety, efficacy, and effectiveness.

摘要

截至2020年9月30日,意大利已确诊超过31.3万例新冠病毒阳性病例,死亡人数超过3.5万,这使意大利成为世界上受影响最严重的国家之一。如此大量的感染和死亡事件,引发了对有效可用治疗方法的迫切需求。发现新冠病毒致病性的细胞/分子机制对于理解感染如何演变为疾病以及如何规划任何治疗方法至关重要。在这方面,我们进行了一项分析,以预测假定的病毒靶点并证明现有的治疗方法。文献实验结果表明,血管紧张素转换酶ACE和刺突蛋白与新冠肺炎特别相关。因此,我们通过查询miRNet(连接微小RNA、靶点和功能的平台)研究了这两种蛋白调节的信号通路。我们的生物信息学分析预测,微小RNA(miRs),即miR-335-5p和miR-26b-5p,会受到刺突蛋白和ACE以及组蛋白去乙酰化酶(HDAC)途径的调节。值得注意的是,我们的结果确定了ACE/ACE2-ATR1-胆固醇-HDAC轴信号,这也与一些现有的临床数据相匹配。我们假设,目前已获欧洲药品管理局批准的用于治疗新冠病毒的非标签HDAC抑制剂(HDACis)药物可被重新利用,以限制或阻断宿主与病毒的相互作用。此外,还提供了一份化合物排名清单,以供进一步评估安全性、疗效和有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08f/7753186/e3bfe1a5db10/fphar-11-582003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08f/7753186/1449927c3ec1/fphar-11-582003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08f/7753186/e3bfe1a5db10/fphar-11-582003-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08f/7753186/1449927c3ec1/fphar-11-582003-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08f/7753186/e3bfe1a5db10/fphar-11-582003-g002.jpg

相似文献

1
MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics.微小RNA生物信息学分析确定HDAC通路为现有抗COVID-19疗法的潜在靶点。
Front Pharmacol. 2020 Dec 8;11:582003. doi: 10.3389/fphar.2020.582003. eCollection 2020.
2
ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors.新型冠状病毒肺炎中的血管紧张素转换酶2相互作用网络:预测心血管危险因素患者预后的生理框架
J Clin Med. 2020 Nov 21;9(11):3743. doi: 10.3390/jcm9113743.
3
Downregulation of ACE, AGTR1, and ACE2 genes mediating SARS-CoV-2 pathogenesis by gut microbiota members and their postbiotics on Caco-2 cells.肠道微生物群及其代谢产物对 Caco-2 细胞介导 SARS-CoV-2 发病机制的 ACE、AGTR1 和 ACE2 基因的下调作用。
Microb Pathog. 2022 Dec;173(Pt A):105798. doi: 10.1016/j.micpath.2022.105798. Epub 2022 Sep 26.
4
Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs.宿主 microRNAs 对 SARS-CoV-2、病毒进入蛋白 ACE2 和 TMPRSS2 及干扰素基因的靶向计算分析。
Genes (Basel). 2020 Nov 16;11(11):1354. doi: 10.3390/genes11111354.
5
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
6
Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.针对血管紧张素转化酶 2(ACE2)受体的不同化合物可能含有 SARS-CoV-2 的感染力:一项计算机研究。
J Mol Model. 2022 Mar 5;28(4):82. doi: 10.1007/s00894-022-05059-1.
7
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).先进的生物信息学可快速为新型冠状病毒肺炎(COVID-19)患者找到现有疗法。
J Transl Med. 2020 Jun 25;18(1):257. doi: 10.1186/s12967-020-02430-9.
8
TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.TGF-β1 通过 miRNA 抑制 ACE2 揭示了 SARS-CoV-2 发病机制的新机制。
J Innate Immun. 2023;15(1):629-646. doi: 10.1159/000533606. Epub 2023 Aug 14.
9
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.涉及 RAS 介导的缓激肽风暴的 COVID-19 的机械模型和治疗干预。
Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177.
10
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.

引用本文的文献

1
A deep learning drug screening framework for integrating local-global characteristics: A novel attempt for limited data.一种用于整合局部-全局特征的深度学习药物筛选框架:针对有限数据的新尝试。
Heliyon. 2024 Jul 14;10(14):e34244. doi: 10.1016/j.heliyon.2024.e34244. eCollection 2024 Jul 30.
2
Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: Epidemiologic and in vitro analysis reveal mechanistic insights.丙戊酸的使用与降低 COVID-19 感染风险和降低疾病严重程度有关:流行病学和体外分析揭示了机制见解。
PLoS One. 2024 Aug 2;19(8):e0307154. doi: 10.1371/journal.pone.0307154. eCollection 2024.
3

本文引用的文献

1
Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?羟氯喹啉和地塞米松用于治疗新型冠状病毒肺炎:谁是赢家,谁是输家?
Clin Mol Allergy. 2020 Sep 9;18:17. doi: 10.1186/s12948-020-00132-7. eCollection 2020.
2
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission.解析 COVID-19:与 SARS-CoV-2 感染和传播相关的组织相关信号通路。
Clin Sci (Lond). 2020 Aug 28;134(16):2137-2160. doi: 10.1042/CS20200904.
3
Management of epigenomic networks entailed in coronavirus infections and COVID-19.
Alteration of circulating ACE2-network related microRNAs in patients with COVID-19.
新型冠状病毒肺炎患者循环 ACE2 网络相关 microRNAs 的变化。
Sci Rep. 2024 Jun 12;14(1):13573. doi: 10.1038/s41598-024-58037-3.
4
SARS-CoV-2 NSP5 antagonizes MHC II expression by subverting histone deacetylase 2.SARS-CoV-2 NSP5 通过颠覆组蛋白去乙酰化酶 2 来拮抗 MHC II 的表达。
J Cell Sci. 2024 May 15;137(10). doi: 10.1242/jcs.262172. Epub 2024 May 22.
5
Comprehensive bioinformatics analysis and systems biology approaches to identify the interplay between COVID-19 and pericarditis.综合生物信息学分析和系统生物学方法鉴定 COVID-19 与心包炎之间的相互作用。
Front Immunol. 2024 Feb 22;15:1264856. doi: 10.3389/fimmu.2024.1264856. eCollection 2024.
6
Discovering common pathogenetic processes between COVID-19 and tuberculosis by bioinformatics and system biology approach.通过生物信息学和系统生物学方法发现 COVID-19 和结核病之间的共同发病机制。
Front Cell Infect Microbiol. 2023 Dec 15;13:1280223. doi: 10.3389/fcimb.2023.1280223. eCollection 2023.
7
Bioinformatics and system biology approach to identify the influences among COVID-19, ARDS and sepsis.生物信息学和系统生物学方法识别 COVID-19、ARDS 和脓毒症之间的影响。
Front Immunol. 2023 May 16;14:1152186. doi: 10.3389/fimmu.2023.1152186. eCollection 2023.
8
Using system biology and bioinformatics to identify the influences of COVID-19 co-infection with influenza virus on COPD.运用系统生物学和生物信息学来识别 COVID-19 与流感病毒合并感染对 COPD 的影响。
Funct Integr Genomics. 2023 May 24;23(2):175. doi: 10.1007/s10142-023-01091-3.
9
Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.与 COVID-19 感染及相关细胞因子风暴相关的表观遗传学观点:最新综述。
Infection. 2023 Dec;51(6):1603-1618. doi: 10.1007/s15010-023-02017-8. Epub 2023 Mar 12.
10
Evaluation of altered miRNA expression pattern to predict COVID-19 severity.评估改变的微小RNA表达模式以预测新冠病毒疾病的严重程度。
Heliyon. 2023 Feb;9(2):e13388. doi: 10.1016/j.heliyon.2023.e13388. Epub 2023 Feb 1.
冠状病毒感染和 COVID-19 中涉及的表观基因组网络的管理。
Clin Epigenetics. 2020 Aug 5;12(1):118. doi: 10.1186/s13148-020-00912-7.
4
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction.针对严重急性呼吸系统综合征冠状病毒 2(COVID-19)病毒刺突蛋白-血管紧张素转换酶 2(ACE2)相互作用的临床试验中天然产物的测试。
Biochem Pharmacol. 2020 Aug;178:114123. doi: 10.1016/j.bcp.2020.114123. Epub 2020 Jun 25.
5
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.重新定位色酮用于COVID-19的早期抗炎治疗
Front Pharmacol. 2020 Jun 5;11:854. doi: 10.3389/fphar.2020.00854. eCollection 2020.
6
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
7
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.七条建议拯救新冠病毒感染患者,降低死亡率:免疫学观点。
Autoimmun Rev. 2020 Jul;19(7):102570. doi: 10.1016/j.autrev.2020.102570. Epub 2020 May 3.
8
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下:一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
9
COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.新型冠状病毒肺炎、肺肥大细胞、细胞因子风暴以及木犀草素的有益作用
Biofactors. 2020 May;46(3):306-308. doi: 10.1002/biof.1633. Epub 2020 Apr 27.
10
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病(COVID-19):综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.